Correlation Between Cue Biopharma and Unity Biotechnology
Can any of the company-specific risk be diversified away by investing in both Cue Biopharma and Unity Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cue Biopharma and Unity Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cue Biopharma and Unity Biotechnology, you can compare the effects of market volatilities on Cue Biopharma and Unity Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cue Biopharma with a short position of Unity Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cue Biopharma and Unity Biotechnology.
Diversification Opportunities for Cue Biopharma and Unity Biotechnology
-0.49 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Cue and Unity is -0.49. Overlapping area represents the amount of risk that can be diversified away by holding Cue Biopharma and Unity Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unity Biotechnology and Cue Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cue Biopharma are associated (or correlated) with Unity Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unity Biotechnology has no effect on the direction of Cue Biopharma i.e., Cue Biopharma and Unity Biotechnology go up and down completely randomly.
Pair Corralation between Cue Biopharma and Unity Biotechnology
Considering the 90-day investment horizon Cue Biopharma is expected to generate 1.23 times more return on investment than Unity Biotechnology. However, Cue Biopharma is 1.23 times more volatile than Unity Biotechnology. It trades about 0.0 of its potential returns per unit of risk. Unity Biotechnology is currently generating about 0.0 per unit of risk. If you would invest 295.00 in Cue Biopharma on September 3, 2024 and sell it today you would lose (173.00) from holding Cue Biopharma or give up 58.64% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Cue Biopharma vs. Unity Biotechnology
Performance |
| Timeline |
| Cue Biopharma |
| Unity Biotechnology |
Cue Biopharma and Unity Biotechnology Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Cue Biopharma and Unity Biotechnology
The main advantage of trading using opposite Cue Biopharma and Unity Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cue Biopharma position performs unexpectedly, Unity Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unity Biotechnology will offset losses from the drop in Unity Biotechnology's long position.| Cue Biopharma vs. DiaMedica Therapeutics | Cue Biopharma vs. Lyra Therapeutics | Cue Biopharma vs. Centessa Pharmaceuticals PLC |
| Unity Biotechnology vs. DiaMedica Therapeutics | Unity Biotechnology vs. Lyra Therapeutics | Unity Biotechnology vs. Centessa Pharmaceuticals PLC |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |